ArticleBioinformatics (Oxford, England)2025
DrugTar improves druggability prediction by integrating large language models and gene ontologies.
Article in Bioinformatics (Oxford, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Integrating evolutionary and compositional features with ML and DL for robust and interpretable druggable protein prediction.Journal of computer-aided molecular design · 2026Article
- The role of AI in oncology: present applications and future horizons.NPJ precision oncology · 2026Review
- DrugProtAI: A machine learning-driven approach for predicting protein druggability through feature engineering and robust partition-based ensemble methods.Briefings in bioinformatics · 2025Article
- DrugGen enhances drug discovery with large language models and reinforcement learning.Scientific reports · 2025Article
- Generative artificial intelligence: In the search for new landscapes in basic and clinical nephrology.Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
motivationTarget discovery is crucial in drug development, especially for complex chronic diseases. Recent advances in high-throughput technologies and the explosion of biomedical data have highlighted the potential of computational druggability prediction methods. However, most current methods rely on sequence-based features with machine learning, which often face challenges related to hand-crafted features, reproducibility, and accessibility. Moreover, the potential of raw sequence and protein structure has not been fully investigated.
resultsHere, we leveraged both protein sequence and structure using deep learning techniques, revealing that protein sequence, especially pre-trained embeddings, is more informative than protein structure. Next, we developed DrugTar, a high-performance deep learning algorithm integrating sequence embeddings from the ESM-2 pre-trained protein language model with gene ontologies to predict druggability. DrugTar achieved areas under the curve and precision-recall curve values of 0.94, outperforming state-of-the-art methods. In conclusion, DrugTar streamlines target discovery as a bottleneck in developing novel therapeutics. AVAILABILITY AND IMPLEMENTATION: DrugTar is available as a web server at www.DrugTar.com. The data and source code are at https://github.com/NBorhani/DrugTar.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.